Characteristic | Level | Overall |
---|---|---|
n | Â | 552 |
Clinical stage, n (%) | Stage I | 342 (62%) |
Stage II | 51 (9.2%) | |
Stage III | 130 (23.6%) | |
Stage IV | 29 (5.3%) | |
Primary therapy outcome, n (%) | PD | 20 (4.2%) |
SD | 6 (1.2%) | |
PR | 12 (2.5%) | |
CR | 442 (92.1%) | |
Age, n (%) | ≤ 60 | 206 (37.5%) |
> 60 | 343 (62.5%) | |
BMI, n (%) | ≤ 30 | 212 (40.8%) |
> 30 | 307 (59.2%) | |
Histological type, n (%) | Endometrioid | 410 (74.3%) |
Mixed | 24 (4.3%) | |
Serous | 118 (21.4%) | |
Histologic grade, n (%) | G1 | 98 (18.1%) |
G2 | 120 (22.2%) | |
G3 | 323 (59.7%) | |
OS event, n (%) | Alive | 458 (83%) |
Dead | 94 (17%) | |
PFI event, n (%) | Alive | 423 (76.6%) |
Dead | 129 (23.4%) | |
Diabetes, n (%) | No | 328 (72.7%) |
Yes | 123 (27.3%) | |
Tumour invasion (%), n (%) |  < 50 | 259 (54.6%) |
≥ 50 | 215 (45.4%) |